Information on EC 3.5.1.5 - urease

New: Word Map on EC 3.5.1.5
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Bacteria, Eukaryota, Archaea

EC NUMBER
COMMENTARY hide
3.5.1.5
-
RECOMMENDED NAME
GeneOntology No.
urease
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
urea + H2O = CO2 + 2 NH3
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
carboxylic acid amide hydrolysis
condensation
-
-
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Arginine biosynthesis
-
-
Atrazine degradation
-
-
Metabolic pathways
-
-
Microbial metabolism in diverse environments
-
-
Purine metabolism
-
-
urea cycle
-
-
urea degradation II
-
-
SYSTEMATIC NAME
IUBMB Comments
urea amidohydrolase
A nickel protein.
CAS REGISTRY NUMBER
COMMENTARY hide
9002-13-5
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
strain WVU45
Uniprot
Manually annotated by BRENDA team
strain WVU45
Uniprot
Manually annotated by BRENDA team
Arthrobacter mobilis
-
-
-
Manually annotated by BRENDA team
Arthrobacter oxydans
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
bacterium strain SL100
gram-positive coccoid isolate prototype with an adhesin specific for gastric mucin
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
urease subunit beta 2; strain 1330, ATCC 23444
UniProt
Manually annotated by BRENDA team
R-SYB082; strain R-SYB082
-
-
Manually annotated by BRENDA team
R-SYB082; strain R-SYB082
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Q75ZQ5: subunit alpha, Q75ZQ6: subunit beta, Q75ZQ4: subunit gamma
Q75ZQ5 and Q75ZQ6 and Q75ZQ4
SwissProt
Manually annotated by BRENDA team
Q75ZQ5: subunit alpha, Q75ZQ6: subunit beta, Q75ZQ4: subunit gamma
Q75ZQ5 and Q75ZQ6 and Q75ZQ4
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
strain 3B1
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
MU-4
-
-
Manually annotated by BRENDA team
MU-4
-
-
Manually annotated by BRENDA team
strain IFO 14511
-
-
Manually annotated by BRENDA team
strain Rt-5
-
-
Manually annotated by BRENDA team
strain PG-98
-
-
Manually annotated by BRENDA team
strain PG-98
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
Proteus mirabilis ATCC 12453
20 clinical isolates
-
-
Manually annotated by BRENDA team
CCM 1956
-
-
Manually annotated by BRENDA team
CCM 1956
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
strain E1F1
-
-
Manually annotated by BRENDA team
strain E1F1
-
-
Manually annotated by BRENDA team
CCM 2056
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
P41022 i.e. subunit A, P41021 i.e. subunit B, P41020 i.e. subunit C
P41022 AND P41021 AND P41020
UniProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
exhibits high urease activity and is capable of growing in urinary condition by forming robust biofilms
-
-
Manually annotated by BRENDA team
Streptococcus mitior
Streptococcus mitior PG-118
PG-118
-
-
Manually annotated by BRENDA team
strain PG-202
-
-
Manually annotated by BRENDA team
strain TH3996
-
-
Manually annotated by BRENDA team
biovar 1A strain
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
metabolism
physiological function
additional information
-
ureases of Canavalia ensiformis are entomotoxic upon the release of internal peptides by insects digestive enzymes
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
hydroxyurea
HCO3- + NH4+ + NH2OH
show the reaction diagram
-
using kinetic isotope effects it is shown that hydroxyurea exhibits biphasic kinetics with a rapid burst phase, followed by a very slow plateau phase. The plateau phase is attributed to irreversible substrate inhibition. The product, hydroxylamine, is shown to be a weak but reversible inhibitor of urease, it is not the cause of the plateau phase
-
-
?
urea + H2O
2 NH3 + CO2
show the reaction diagram
urea + H2O
?
show the reaction diagram
urea + H2O
ammonia + CO2
show the reaction diagram
-
-
-
-
-
urea + H2O
CO2 + 2 NH3
show the reaction diagram
urea + H2O
CO2 + NH3
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
urea + H2O
?
show the reaction diagram
urea + H2O
CO2 + 2 NH3
show the reaction diagram
urea + H2O
CO2 + NH3
show the reaction diagram
-
role for urease and urease-derived ammonia in megasome formation and survival of Helicobacter pylori in murine peritoneal macrophages and J774 cells
-
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Ca2+
-
enhances activity
K+
-
assay with 200 mM KCl
Mg2+
-
enhances activity
Mn2+
-
enhances activity
NaCl
-
maximum activity at 18-23% NaCl at 50C, loses activity irreversibly in the absence of NaCl
additional information
-
urease apoprotein binds numerous metal ions
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2-[[(2-[[2-(hydroxy-kappaO)ethyl]amino-kappaN]ethyl)imino-kappaN]methyl]-4-nitrophenolato-kappaO)(methoxymethanolato-kappaO)zinc
-
-
(2-[[(2-[[2-(hydroxy-kappaO)ethyl]amino-kappaN]ethyl)imino-kappaN]methyl]-4-nitrophenolato-kappaO)(nitrato-kappaO)copper
-
-
(2E)-3-(1,3-benzodioxol-5-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2S)-2-(dimethylamino)-3-(ethylthio)propan-1-ol
(2S)-2-(dimethylamino)-3-ethoxypropane-1-thiol
(2S)-2-(dimethylamino)-3-mercaptopropan-1-ol
(2S)-2-(dimethylamino)-3-methoxypropane-1-thiol
(aminomethyl)methylphosphinic acid
-
-
(aminomethyl)phosphonic acid
(E)-1-((E)-3-phenylallylidene)thiosemicarbazide
-
-
-
(E)-1-(2-chlorobenzylidene)thiosemicarbazide
-
-
(E)-1-(3,4,5-trimethoxybenzylidene)thiosemicarbazide
-
-
-
(E)-1-(3-bromobenzylidene)thiosemicarbazide
-
-
(E)-1-(3-chlorobenzylidene)thiosemicarbazide
-
-
(E)-1-(3-methoxybenzylidene)thiosemicarbazide
-
-
-
(E)-1-(3-nitrobenzylidene)thiosemicarbazide
-
competitive mechanism of inhibition
-
(E)-1-(4-(N,N-dimethylamino)benzylidene)thiosemicarbazide
-
-
-
(E)-1-(4-bromobenzylidene)thiosemicarbazide
-
-
(E)-1-(4-chlorobenzylidene)thiosemicarbazide
-
-
(E)-1-(4-methoxybenzylidene)thiosemicarbazide
-
-
-
(E)-1-(4-nitrobenzylidene)thiosemicarbazide
-
-
-
(E)-2-((E)-but-2-enylidene) hydrazinecarbothioamide
-
-
-
(E)-2-(2,3-dihydroxybenzylidene)hydrazinecarbothioamide
-
-
-
(E)-2-(2-(benzyloxy)benzylidene)hydrazinecarbothioamide
-
-
-
(E)-2-(3-(benzyloxy)-4-methoxybenzylidene)hydrazinecarbothioamide
-
-
-
(E)-2-(4-hydroxy-3,5-dimethoxybenzylidene)hydrazinecarbothioamide
-
-
-
(E)-2-(4-hydroxybenzylidene)hydrazinecarbothioamide
-
-
-
(R)-4-methoxydalbergione
(R)-dalbergiophenol
([[(benzyloxy)carbonyl]amino]methyl)methylphosphinothioic O-acid
1'-(trifluoroacetyl)-1,4'-bipiperidine
-
50% inhibition at 0.061 mM
1,1-dimethyl-3-[(1S)-1-naphthalen-1-ylethyl]selenourea
-
-
1,10-phenanthroline
-
5 mM, 67% inhibition
1,3-bis(3-chlorophenyl)thiourea
-
-
1,4-Naphthoquinone
-
-
1-(2,4-difluorophenyl)-3-phenylthiourea
-
-
1-(2,4-dihydroxyphenyl)-2-(4-fluorophenyl)ethanone oxime
-
-
1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone
-
0.4 mg/ml, 16% inhibition
1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone oxime
-
-
1-(2,5-dimethoxyphenyl)-3-phenylthiourea
-
-
1-(2-chlorophenyl)-3-(3-chlorophenyl)thiourea
-
-
1-(2-chloropyridin-3-yl)-3-phenylthiourea
-
-
1-(2-hydroxy-4,6-dimethoxyphenyl)-2-(4-methoxyphenyl)ethanone oxime
-
-
1-(3,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone
-
0.4 mg/ml, 39% inhibition
1-(3,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone oxime
-
-
1-(3,5-dichloropyridin-2-yl)-3-phenylthiourea
-
-
1-(3-bromophenyl)-3-phenylthiourea
-
-
1-(3-chlorophenyl)-3-(2,3-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,4-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,4-dimethylphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,5-dimethylphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,6-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2,6-dimethylphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(2-chloropyridin-3-yl)thiourea
-
-
1-(3-chlorophenyl)-3-(2-methoxyphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3,4-dichlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3,4-difluorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3-methoxyphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(3-methylpyridin-2-yl)thiourea
-
-
1-(3-chlorophenyl)-3-(4-chlorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(4-fluorophenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(4-methoxyphenyl)thiourea
-
-
1-(3-chlorophenyl)-3-(m-tolyl)thiourea
-
-
1-(3-chlorophenyl)-3-(o-tolyl)thiourea
-
-
1-(3-chlorophenyl)-3-(p-tolyl)thiourea
-
-
1-(3-chlorophenyl)-3-(pyridin-3-yl)thiourea
-
-
1-(3-chlorophenyl)-3-(pyridin-3-ylmethyl)thiourea
-
-
1-(3-chlorophenyl)-3-(pyridin-4-ylmethyl)thiourea
-
-
1-(3-methylpyridin-2-yl)-3-phenylthiourea
-
-
1-(4-bromophenyl)-3-phenylthiourea
-
-
1-(5-bromo-6-methylpyridin-2-yl)-3-phenylthiourea
-
-
1-(5-chloro-2-methylphenyl)-3-(3-chlorophenyl)thiourea
-
-
1-(furan-2-ylmethyl)-3-phenylthiourea
-
-
1-benzyl-2-ethyl-6,6-dimethyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-benzyl-2-ethyl-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-cyclohexyl-3,3-dimethyl-1-(1-methylethyl)selenourea
-
-
1-ethoxy-2-ethyl-6,6-dimethyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-ethoxy-2-ethyl-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
1-phenyl-3-(pyridin-2-yl)thiourea
-
-
1-phenyl-3-(pyridin-3-yl)thiourea
-
-
1-phenyl-3-(pyridin-3-ylmethyl)thiourea
-
-
1-phenyl-3-(pyridin-4-yl)thiourea
-
-
1-phenyl-3-(pyridin-4-ylmethyl)thiourea
-
-
12-hydroxytetradecanoc acid
-
48.47% inhibition at 100 ng/ml
-
2',4',5',7-tetramethoxyisoflavone
-
-
-
2,2'-bi-1,3,4-oxadiazole-5,5'(4H,4'H)-dithione
2,2'-bi-1,3,4-thiadiazole-5,5'(4H,4'H)-dithione
2,2'-thenoin
-
IC50: 0.18 mM
2,3,4,4'-tetrahydroxydeoxybenzoin
-
0.4 mg/ml, 51% inhibition
2,3,4-trihydroxy-4'-methoxydeoxybenzoin
-
0.4 mg/ml, 44% inhibition
2,4,4',6-tetrahydroxy-3-methoxyphenyldeoxybenzoin
-
0.4 mg/ml, 17% inhibition
2,4,6-trihydroxy-9H-xanthen-9-one
-
-
2,4,6-trimethyl-N-([1-[(2,4,6-trimethylphenyl)sulfonyl]piperidin-4-yl]methyl)benzenesulfonamide
-
50% inhibition at 0.038 mM
2,4-dihydroxy-40-methoxydeoxybenzoin
-
0.4 mg/ml, 14% inhibition
-
2,4-dihydroxyacetophenone
-
0.4 mg/ml, 14% inhibition
2,4-diphenyl-2,3-dihydro-1,5-benzothiazepine
-
-
2-(1-amino-2-(4-hydroxyphenyl)ethyl)-4-methoxybenzene-1,3,5-triol
-
-
2-(1-amino-2-(4-hydroxyphenyl)ethyl)benzene-1,3,5-triol
-
-
2-(4-fluorophenyl)-1-(2,3,4-trihydroxyphenyl)ethanone oxime
-
-
2-(4-hydroxyphenyl)-1-(2,3,4-trihydroxyphenyl)ethanone oxime
-
-
2-(4-hydroxyphenyl)-1-(2,4,6-trihydroxy-3-methoxyphenyl)ethanone oxime
-
-
2-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)ethanone oxime
-
-
2-(4-methoxyphenyl)-1-(2,3,4-trimethoxyphenyl)ethanamine
-
-
2-(4-methylphenyl)-4-phenyl-2,3-dihydro-1,5-benzothiazepine
-
-
2-(4-nitrophenyl)-4-phenyl-2,3-dihydro-1,5-benzothiazepine
-
-
2-ethyl-1-(2-phenylethyl)-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-ethyl-1-(4-methoxycyclohexyl)-6,6-dimethyl-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-ethyl-1-(4-methoxyphenyl)-6-(2,4,6-trimethylphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-ethyl-6-[2-(ethylsulfanyl)propyl]-1-(4-methoxyphenyl)-1,5,6,7-tetrahydro-4H-benzimidazol-4-one
-
reversible and competitive inhibitor
2-hydroxy-1-phenylethanone
-
IC50: 0.47 mM
2-mercaptoethanol
2-thioxo-5-(2,3,4-trihydroxybenzylidene)dihydro-4,6(1H,5H)-pyrimidinedione
-
-
2-[(1E)-N-(allyloxy)butanimidoyl]-5,5-dimethylcyclohexane-1,3-dione
-
chelator of the nickel atom in enzyme metallocenter
2-[(1E)-N-ethoxybutanimidoyl]-5,5-dimethylcyclohexane-1,3-dione
-
chelator of the nickel atom in enzyme metallocenter
2-[(2S,4R)-2-(4-fluorophenyl)-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-yl]phenol
-
-
2-[(2S,4R)-2-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-4-yl]phenol
-
-
2-[2-(1,3-benzodioxol-5-yl)-2,3-dihydro-1,5-benzothiazepin-4-yl]phenol
-
-
2-[2-(3,4-dimethoxyphenyl)ethyl]phenol
-
-
3,3'-(1H-indol-3-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(1H-pyrrol-2-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(2-bromobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-chlorobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-methoxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-phenylpropane-1,1-diyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(2-phenylpropylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-pyridyl-methylene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2-pyrolidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(2E)-but-2-ene-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(3-chlorobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-cinnamylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-hydroxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-indolidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-methoxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(3-phenylpropane-1,1-diyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(4-hydroxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(4-methoxybenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(4-nitrobenzylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(crotonalidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(dihydrocinnamylidene)-bis-(4-hydroxycoumarin)
-
-
3,3'-(naphthalen-1-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(pyridin-3-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-(pyridin-4-ylmethanediyl)bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-butane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-ethane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-ethylidenebis-(4-hydroxycoumarin)
-
-
3,3'-hexane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-methylenebis-(4-hydroxycoumarin)
-
-
3,3'-n-butylidene-bis(4-hydroxycoumarin)
-
-
3,3'-n-hexylidene-bis(4-hydroxycoumarin)
-
-
3,3'-n-pentylidene-bis(4-hydroxycoumarin)
-
-
3,3'-pentane-1,1-diylbis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(1E)-1-phenylprop-1-ene-3,3-diyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(2-bromophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(2-chlorophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(2-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3,4,5-trimethoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3,4-dimethoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-aminophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-chlorophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-ethoxy-4-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(3-nitrophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-hydroxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-methoxyphenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[(4-nitrophenyl)methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[4-(1-methylethyl)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,3'-[[4-(dimethylamino)phenyl]methanediyl]bis(4-hydroxy-2H-chromen-2-one)
-
-
3,4,5-trihydroxy-9H-xanthen-9-one
-
-
3,4,5-Trihydroxybenzoate
3,4-Dihydroxyacetophenone
-
0.4 mg/ml, 41% inhibition
3,5-dimethylphenyl diamidophosphate
-
-
3-(4-bromobenzyl)-1,1-dimethylselenourea
-
-
3-(4-bromophenyl)-1,1-dimethylthiourea
-
-
3-dodecyl-1,1-dimethylthiourea
-
-
3-hydroxytetradecanoc acid
-
49.20% inhibition at 100 ng/ml
-
3-methyl-N-[[1-(3-methylbut-2-en-1-yl)piperidin-4-yl]methyl]but-2-en-1-amine
-
50% inhibition at 0.063 mM
3-phenoxy-N-[[1-(3-phenoxypropyl)piperidin-4-yl]methyl]propan-1-amine
-
50% inhibition at 0.043 mM
3-[(2-acetylanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
-
54% inhibition at 0.01 mM
3-[(2-fluoroanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
-
44% inhibition at 0.01 mM
3-[(3-acetylanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
-
28% inhibition at 0.01 mM
3-[(3-fluoroanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]-pyrimidine-2,4-dione
-
3% inhibition at 0.01 mM
3-[(4-acetylanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4-dione
-
5% inhibition at 0.01 mM
3-[(4-fluoroanilino)methylidene]-8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4-dione
-
21% inhibition at 0.01 mM
-
3-[(mesitylamino)methylidene]-8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4-dione
-
-
4'-O-methylalpinumisoflavone
-
-
-
4'-O-methylderrone
-
-
-
4-(1-amino-2-(4-fluorophenyl)ethyl)benzene-1,2,3-triol
-
-
-
4-(1-amino-2-(4-fluorophenyl)ethyl)benzene-1,3-diol
-
-
4-(1-amino-2-(4-hydroxyphenyl)ethyl)benzene-1,2,3-triol
-
-
4-(1-amino-2-(4-hydroxyphenyl)ethyl)benzene-1,2-diol
-
-
4-(1-amino-2-(4-methoxyphenyl)ethyl)benzene-1,3-diol
-
-
4-(2,3-dimethylphenyl)-5-phenyl-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(2,4-dichlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(2,4-difluorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(2,4-dimethylphenyl)-5-(3-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(2,5-dichlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3,4-dichlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3,4-difluorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3,4-dimethoxyphenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(3-aminophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-benzoyl-5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)phenyl benzoate
4-(4-bromophenyl)-5-[hydroxy(phenyl)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(4-bromophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-chlorophenyl)-5-[hydroxy(phenyl)methyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
4-(4-chlorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-fluorophenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(4-methoxyphenyl)-6-(9-methyl-9H-carbazol-3-yl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(2,4,6-trimethoxyphenyl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(4-nitrophenyl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(pyridin-2-yl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-(thiophen-2-yl)-pyrimidin-2-amine
-
-
4-(9-methyl-9H-carbazol-3-yl)-6-phenylpyrimidin-2-amine
-
-
4-(benzyloxy)phenyl diamidophosphate
-
-
4-(p-hydroxyphenethyl)pyrogallol
-
0.4 mg/ml, 94.5% inhibition
4-amino-5-(4-hydroxyphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
4-amino-5-pyridin-4-yl-2,4-dihydro-3H-1,2,4-triazole-3-thione
4-bromo-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]benzohydrazide
-
23% inhibition at 0.01 mM
4-bromophenylboronic acid
4-butylbenzene-1,2,3-triol
-
-
4-butylbenzene-1,2-diol
-
-
4-chloro-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]benzohydrazide
-
14% inhibition at 0.01 mM
4-decylbenzene-1,2,3-triol
-
-
4-dodecylbenzene-1,2,3-triol
-
-
4-ethylbenzene-1,2,3-triol
-
-
4-ethylbenzene-1,2-diol
-
-
4-hexylbenzene-1,2,3-triol
-
-
4-hexylbenzene-1,2-diol
-
-
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)-3-phenylprop-2-en-1-yl]-2H-chromen-2-one
4-hydroxy-3-[(2E)-1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)but-2-en-1-yl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-indol-3-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(1H-pyrrol-3-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(3-methoxyphenyl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)(pyridin-4-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)methyl]-2H-chromen-2-one
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)ethyl]-2H-chromen-2-one
4-hydroxy-3-[1-(4-hydroxy-2-oxo-4a,8a-dihydro-2H-chromen-3-yl)pentyl]-2H-chromen-2-one
4-hydroxy-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]benzohydrazide
-
22% inhibition at 0.01 mM
4-methyl-N-([1-[(4-methylphenyl)sulfonyl]piperidin-4-yl]methyl)benzenesulfonamide
-
50% inhibition at 0.042 mM
4-nitro-N'-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl] benzohydrazide
-
60% inhibition at 0.01 mM
4-nitro-N-([1-[(4-nitrophenyl)sulfonyl]piperidin-4-yl]methyl)benzenesulfonamide
-
50% inhibition at 0.032 mM
4-nitrophenyl diamidophosphate
-
-
4-octylbenzene-1,2,3-triol
-
-
4-octylbenzene-1,2-diol
-
-
4-tetradecylbenzene-1,2,3-triol
-
-
4-[2-(3,4-diethoxyphenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3,4-dimethoxyphenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3,4-dimethoxyphenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(3,4-dimethoxyphenyl)ethyl]phenol
-
-
4-[2-(3-bromophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3-bromophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(3-chlorophenyl)ethyl]-1,2-dimethoxybenzene
-
-
4-[2-(3-chlorophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(3-chlorophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(4-bromophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-chlorophenyl)ethyl]-1,2-dimethoxybenzene
-
-
4-[2-(4-chlorophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-chlorophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(4-fluorophenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-fluorophenyl)ethyl]benzene-1,2-diol
-
-
4-[2-(4-hydroxyphenyl)ethyl]benzene-1,2,3-triol
-
-
4-[2-(4-hydroxyphenyl)ethyl]benzene-1,2-diol
-
-
5-(1,4-dihydro-9-anthracenylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(1-naphthyl)-1,3,4-oxadiazole-2(3H)-thione
5-(1H-indol-3-ylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2,4-dihydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-aminobenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-bromo-4,5-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-chlorophenyl)-N-(2,6-dimethylphenyl)-1,3,4-thiadiazol-2-amine
-
-
5-(2-hydroxy-3-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-hydroxy-5-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-methylbenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(2-thienylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,4-dihydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,4-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,5-dibromo-4-hydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3,5-dichloro-2-hydroxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3-chlorophenyl)-4-(2,4-dimethylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(3-chlorophenyl)-4-(2,6-dimethylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(3-hydroxy-4-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
5-(4-bromo-2,5-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-chlorophenyl)-4-(2,4-dimethylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-(4-chlorophenyl)-N-(2,3-dimethylphenyl)-1,3,4-thiadiazol-2-amine
-
-
5-(4-chlorophenyl)-N-(2,6-dimethylphenyl)-1,3,4-thiadiazol-2-amine
-
-
5-(4-ethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-hydroxy-3,5-dimethoxybenzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-hydroxy-3-iodo-5-methoxybenzylidene)-2-thioxodihydro-4,6(1H,5H) pyrimidinedione
-
-
5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione
5-(4-hydroxyphenyl)-1,3,4-thiadiazole-2(3H)-thione
-
-
5-(4-propoxyphenyl)-3-propyl-1,3,4-thiadiazole-2(3H)-thione
-
-
5-(4-pyridinylmethylene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-(4-[[4,6-dioxo-2-thioxotetrahydro-5(2H)pyrimidinylidene]methyl]-benzylidene)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione
5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione
5-benzyl-1,3,4-oxadiazole-2(3H)-thione
5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione
5-hydroxy-1,4-naphthoquinone
-
5-hydroxy-1,4-naphthoquinone, juglone, acts as a strong, time and concentration dependent inactivator of urease. The reactivation of juglone-modified urease shows the participation of reversible and irreversible contribution in the inactivation. In the presence of an excess of DTT, urease inactivated by juglone regains 70% of its activity. The reversible inactivation is attributed to oxidation of the essential urease thiols by reactive oxygen species (ROS) realizing during reduction of juglone to seminaphthoquinone. The irreversible contribution in the inhibition is assumed as an arylation of urease thiol groups by juglone
5-phenyl-1,3,4-oxadiazole-2(3H)-thione
5-phenyl-1,3,4-thiadiazole-2(3H)-thione
5-pyridin-4-yl-1,3,4-oxadiazole-2(3H)-thione
5-pyridin-4-yl-1,3,4-thiadiazole-2(3H)-thione
5-[(2-hydroxy-1-naphthyl)methylene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-[(5-methyl-2-furyl)methylene]-2-thioxodihydro-4,6(1H,5H)pyrimidinedione
-
-
5-[(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl]-1,3,4-oxadiazole-2(3H)-thione
5-[(5-thioxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)methyl]-1,3,4-thiadiazole-2(3H)-thione
5-[(6-bromo-4-chloro-2-oxo-2H-chromen-3-yl)methylene]-2-thioxodihydro 4,6(1H,5H)-pyrimidinedione
-
-
5-[(6-methyl-2-pyridinyl)methylene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-[3-(5-thioxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)propyl]-1,3,4-oxadiazole-2(3H)-thione
5-[3-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione
-
-
5-[4(dimethylamino) benzylidene]-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
-
-
5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazole-2(3H)-thione
5-[4-(methylsulfanyl)benzylidene]-2-thioxodihydro-4,6(1H,5H) pyrimidinedione
-
-
5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3H-[1,3,4]oxadiazole-2-thione
5-[4-(tert-butyl-dimethyl-silanyloxy)-phenyl]-3H-[1,3,4]thiadiazole-2-thione
-
-
5-[hydroxy(phenyl)methyl]-4-(4-methylphenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
5-[hydroxy(phenyl)methyl]-4-(4-nitrophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione
-
-
6-(1-hydroxy-2-(4-methoxyphenyl)ethyl)-2,3-dimethoxyphenol
-
0.4 mg/ml, 42% inhibition
6-hydroxytetradecanoc acid
-
59.01% inhibition at 100 ng/ml
-
6a,12a-dehydroxydegueline
-
-
-
7'-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7-yl alpha-L-mannopyranoside
7'-hydroxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside
7'-methoxy-2,2'-dioxo-3'-[(2-oxo-2H-chromen-7-yl)oxy]-2H,2'H-8,8'-bichromen-7-yl alpha-D-glucopyranoside
7,8,4'-trihydroxyisoflavone
-
0.4 mg/ml, 81.7% inhibition
7-hydroxy-2,2'-dioxo-2H,2'H-6,8'-bichromen-7'-yl alpha-L-mannopyranoside
7-hydroxytetradecanoc acid
-
53.43% inhibition at 100 ng/ml
-
7-O-methylcuneantin
-
-
-
7-[(7-methoxy-2-oxo-2H-chromen-3-yl)oxy]-2-oxo-2H-chromen-6-yl alpha-D-glucopyranoside
8-hydroxy-3-[(6-hydroxy-2-oxo-2H-chromen-7-yl)oxy]-2-oxo-2H-chromen-7-yl beta-D-glucopyranoside
8-methyl-2H-pyrido[1,2-a]pyrimidine-2,4(3H)-dione
-
26% inhibition at 0.01 mM
8-methyl-3-[(2-sulfanylanilino)methylidene]-2H-pyrido[1,2-a]pyrimidine-2,4-dione
-
73% inhibition at 0.01 mM
8-methyl-3-[[(4-methyl-2-pyridinyl)amino]methylidene]-2Hpyrido[1,2-]pyrimidine-2,4-dione
-
20% inhibition at 0.01 mM
8-methyl-3-[[(5-methyl-2-pyridinyl)amino] methylidene]-2H-pyrido[1,2-]pyrimidine-2,4-dione
-
48% inhibition at 0.01 mM
8-methyl-3-[[(5-nitro-2-pyridinyl)amino] methylidene]-2H-pyrido[1,2-a]pyrimidine-2,4-dione
-
36% inhibition at 0.01 mM
9-hydroxytetradecanoc acid
-
52.97% inhibition at 100 ng/ml
-
Acetohydroxamate
Acetohydroxamic acid
acetol
-
IC50: 2.9 mM
Allicin
-
from garlic, inhibits the biofilm formation and urease activity in vitro in both prelysed and intact cells. A higher concentration of allicin is needed to inhibit the established biofilms
alpinumisoflavone
-
-
aminomethyl(P-methyl)phosphinic acid
atalantoflavone
-
-
-
avicularin
-
-
Ba2+
-
-
beta-(o-methoxyphenyl)-gamma,gamma-bis(8-quinolinoxy)germa-gamma-lactone
-
inhibition occurrs in a noncompetitive and concentration-dependent manner. Highly selective in inhibiting the growth of Proteus mirabilis at moderate concentrations. Potential to be developed as antimicrobial agents against Proteus mirabilis infection
beta-(o-methylphenyl)-gamma,gamma-bis(8-quinolinoxy)germa-gamma-lactone
-
inhibition occurrs in a noncompetitive and concentration-dependent manner. Highly selective in inhibiting the growth of Proteus mirabilis at moderate concentrations. Potential to be developed as antimicrobial agents against Proteus mirabilis infection
Boric acid
butylboronic acid
Ca2+
-
-
Calopogonium isoflavone A
-
-
-
chloro(2-[[(2-[[2-(hydroxy-kappaO)ethyl]amino-kappaN]ethyl)imino-kappaN]methyl]-4-nitrophenolato-kappaO)copper
-
-
citrate
P41022 AND P41021 AND P41020
binding of the ligand to the active site involves stabilizing interactions, such as a carboxylate group that binds the nickel ions at the active site and several hydrogen bonds with the surrounding residues
citrate buffer
-
-
cyanide
-
1.0 mM, 32% inhibition
daidzeine
-
-
-
dehydroascorbic acid
-
inhibitory action of dehydroascorbic acid is revealed in the presence of Fe3+ ions and found to be primarily mediated by H2O2. The resulting inhibition by dehydroascorbic acid -Fe3+ consists of enzyme thiol oxidation and its effectiveness grew with increasing pH
ethyl 4-(3-benzoylthioureido) benzoate
-
-
ethyl 4-[3-(2,4-dichlorobenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(2-bromobenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(2-fluorobenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(3,4-dimethoxybenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(3-chlorobenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(3-methoxybenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(3-methylbenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(4-methoxybenzoyl)thioureido]benzoate
-
-
ethyl 4-[3-(4-methylbenzoyl)thioureido]benzoate
-
-
fluoride
furoin
-
IC50: 0.36 mM
gallacetophenone
-
0.4 mg/ml, 38% inhibition
guaijaverin
-
-
Hpn protein
-
synthesis and purifcation of the 7 kDa protein, the synthetic nickel-binding histidine-rich protein designated Hpn is capable of abrogating urease activity of live Heicobacter pylori in liquid cultures due to inhibition of nickel uptake into cells
-
hydroxamic acid
-
1.0 mM, 64% inhibition
hydroxylamine
Hydroxyurea
iodoacetamide
-
phosphate protects wild-type enzyme from inactivation, does not affect inactivation of C319S urease
isoquercitrin
-
-
L-ascorbic acid
-
in an unbuffered system L-ascorbic acid inactivates urease in a biphasic manner by denaturation brought about by ascorbic acid-lowered pH. In a buffered system neither ascorbic acid nor dehydroascorbic acid themselves are inhibitors of urease
L-aspartyl-4-hydroxamate
L-glutamine
-
50 mM, 14% inhibition
L-glutamyl-5-hydroxamate
-
50 mM, 34% inhibition
-
L-Gly hydroxamate
mercaptoethylamine
-
inactivates enzyme irreversibly
methyl (7E)-7-[4,4-dimethyl-3-(3-methylisoxazol-5-yl)-2,6-dioxocyclohexyl]-7-(ethoxyimino)heptanoate
-
chelator of the nickel atom in enzyme metallocenter
methyl 2-amino-4,5,6,7,8,9-hexahydrocycloocta[b]thiophene-3-carboxylate
methyl 2-amino-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-amino-4-methylthiophene-3-carboxylate
methyl 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
methyl 2-amino-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate
methyl 2-[(methoxycarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[bis(chlorocarbonyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[[(chloromethoxy)carbonyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[[(chloromethoxy)carbonyl]amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate
methyl 2-[[(dichloromethoxy)carbonyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 2-[[(methylsulfanyl)carbonothioyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
methyl 3-(4-[[(3-methoxy-3-oxopropyl)amino]methyl]piperidin-1-yl)propanoate
-
50% inhibition at 0.019 mM
methyl 5-[(1E)-N-(allyloxy)butanimidoyl]-2,2-dimethyl-4,6-dioxocyclohexanecarboxylate
-
chelator of the nickel atom in enzyme metallocenter
methyl 5-[(1E)-N-ethoxybutanimidoyl]-2,2-dimethyl-4,6-dioxocyclohexanecarboxylate
-
chelator of the nickel atom in enzyme metallocenter
methyl 5-[(1E)-N-ethoxyethanimidoyl]-2,2-dimethyl-4,6-dioxocyclohexanecarboxylate
-
chelator of the nickel atom in enzyme metallocenter
methyl[(methylamino)methyl]phosphinic acid
Mg2+
-
-
N-(1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(2,3-dimethylphenyl)-5-phenyl-1,3,4-thiadiazol-2-amine
-
-
N-(2,4-dimethylphenyl)-5-(3-nitrophenyl)-1,3,4-thiadiazol-2-amine
-
-
N-(2-methoxy-4-nitrophenyl)phosphoric triamide
-
-
N-(2-nitrophenyl)phosphoric triamide
-
-
N-(2-phenylethyl)phosphoric triamide
-
-
N-(2-phenylethyl)phosphorothioic triamide
-
-
N-(3-chlorophenyl)-N0-(4-methoxyphenyl)thiourea
-
-
-
N-(3-methoxyphenyl)phosphoric triamide
-
-
N-(3-methylpyridin-2-yl)phosphorothioic triamide
-
-
N-(3-morpholin-2-ylpropyl)phosphoric triamide
-
-
N-(3-nitropyridin-2-yl)phosphoric triamide
-
-
N-(4-cyclohexylphenyl)phosphoric triamide
-
-
N-(4-methoxy-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(4-methyl-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(4-methyl-2-nitrophenyl)phosphoric triamide
-
-
N-(4-nitrophenyl)phosphoric triamide
-
-
N-(4-phenoxyphenyl)phosphoric triamide
-
-
N-(6-ethoxy-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(6-fluoro-1,3-benzothiazol-2-yl)phosphoric triamide
-
-
N-(N'-benzyloxycarbonylglycyl)aminomethyl(P-methyl)phosphinothioic acid
N-1,3-benzothiazol-2-ylphosphoric triamide
-
-
N-1,3-benzothiazol-2-ylphosphorothioic triamide
-
-
N-adamant-1-ylphosphoric triamide
-
-
N-benzyloxycarbonylaminomethyl(P-methyl)phosphinic acid
N-dimethyl-L-cysteine
N-dimethyl-S-methyl-L-cysteine
N-ethylmaleimide
-
irreversible inactivation
N-glycyl-aminomethyl(P-methyl)phosphinic acid
N-hydroxyacetamide
-
-
N-n-butylphosphoric triamide
-
-
N-n-butylthiophosphoric triamide
-
-
N-naphthalen-1-ylphosphoric triamide
-
-
N-phenylphosphoric triamide
-
-
N-[2-(4-fluorophenyl)ethyl]phosphoric triamide
-
-
N-[2-(difluoromethoxy)phenyl]phosphoric triamide
-
-
N-[2-(trifluoromethoxy)phenyl]phosphoric triamide
-
-
N-[4-(benzyloxy)phenyl]phosphoric triamide
-
-
N-[[hydroxy(methyl)phosphoryl]methyl]-L-phenylalaninamide
N-[[hydroxy(methyl)phosphoryl]methyl]-L-serinamide
N-[[hydroxy(methyl)phosphoryl]methyl]-L-valinamide
N2-[(benzyloxy)carbonyl]-N-[[hydroxy(methyl)phosphoryl]methyl]glycinamide
N-[[8-methyl-2,4-dioxo-2H-pyrido[1,2-a]pyrimidin-3(4H)-ylidene]methyl]-benzo-hydrazide
-
13% inhibition at 0.01 mM
-
O-benzyl-N-[[hydroxy(methyl)phosphoryl]methyl]-L-serinamide
O-[4-(benzyloxy)phenyl] diamidothiophosphate
-
-
p-benzoquinone
-
-
p-chloromercuribenzene sulfonate
-
0.1 mM, complete inhibition
p-hydroxymercuribenzoate
Pb2+
-
inhibitory effect of heavy metals over immobilized enzyme decreases in the order Cu2+, Cd2+, Zn2+, Ni2+, Pb2+
PCMB
-
0.1 mM, complete loss of activity
peptides
-
TFLPQPRCSALLRYLSEDGVIVPS and YDFYWW, no inhibition of the enzyme from Bacillus pasteurii and Canavalia ensiformis
phenylboronic acid
phenylphosphoramidate
-
-
phenylphosphorodiamidate
Phenylurea
-
weak non-competitive
Phosphoramidate
-
-
psi-tectorigenin
-
0.4 mg/ml, 36% inhibition
quercetin-4'-O-beta-D-glucopyranoside
-
-
quercitrin
-
-
S-ethyl-L-cysteine
Selenourea
-
50 mM, 80% inhibition
Semicarbazide
Sr2+
-
-
tetrachloro-o-benzoquinone
-
no recovery of urease activity bound in the urease-inhibitor complex after dilution or addition of dithiothreitol
tetrachloro-p-benzoquinone
-
-
tetracosyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
-
-
Thiourea
triphenylbismuth difluoride
-
first-order rate constant for inactivation 0.00158 per s
tris(2,4,6-trimethylphenyl)bismuth
-
first-order rate constant for inactivation 0.0027 per s
tris(4-fluorophenyl)bismuth dichloride
-
first-order rate constant for inactivation 0.00158 per s
tris(4-fluorophenyl)bismuth difluoride
-
first-order rate constant for inactivation 0.00259 per s
tris(4-methylphenyl)bismuth dichloride
-
first-order rate constant for inactivation 0.00259 per s
[(acetylamino)methyl]methylphosphinic acid
[(acetylamino)methyl]phosphonic acid
-
-
[(benzylamino)methyl]methylphosphinic acid
[(dimethylamino)methyl]methylphosphinic acid
[(dimethylamino)methyl]phosphonic acid
[(methylamino)methyl]phosphonic acid
[5-[(4-methylphenyl)amino]-1,3,4-oxadiazol-2-yl](phenyl)methanol
-
-
[5-[(4-nitrophenyl)amino]-1,3,4-oxadiazol-2-yl](phenyl)methanol
-
-
[[benzyl(methyl)amino]methyl]phosphonic acid
-
-
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
EDTA
-
slight stimulation
glycerol
-
optimum concentration: 15%
n-octylglucoside
-
optimum concentration: 0.1%
PEG
-
optimum concentration: 0.5%
SDS
-
optimum concentration: 0.02%
Triton X-100
-
optimum concentration: 0.05%
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0195 - 2090
Urea
additional information
additional information